Skip to main content
PharmSpace

Class Explorer · Anti-infectives

Fluoroquinolones

DNA gyrase/topoisomerase IV inhibitors: concentration-dependent killing, excellent oral bioavailability.

Members

Also in this class: Levofloxacin (respiratory) · Moxifloxacin (respiratory, no urinary role, most QT). Full pages arrive as the library grows.

Compare the members

Ciprofloxacin
Niche
Gram-negative, urinary
Distinguishing point
Weakest respiratory (pneumococcus) activity

Shared across the class

Indications
Complicated UTI/pyelonephritis · Selected respiratory and GI infections, increasingly reserve agents
Adverse effects
Tendinopathy · QT prolongation · CNS effects · C. difficile · Cation chelation (administration failure)
Contraindications
Prior quinolone tendinopathy
Monitoring
Tendon pain · QT-relevant co-medication · 48-72 h response

What makes each agent different

  • Ciprofloxacin owns gram-negatives and urine; moxifloxacin owns the chest and never the bladder (no urinary concentration).
  • QT ranking: moxifloxacin > levofloxacin > ciprofloxacin.

Every fluoroquinolone counselling session includes the dairy/antacid separation speech.

Last reviewed 2026-08-15 · Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed.